Download PDF
Thromb Haemost 2019; 119(03): 397-406
DOI: 10.1055/s-0039-1677744
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib

Viola Denzinger
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
,
Kristina Busygina
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
,
Janina Jamasbi
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
,
Isabell Pekrul
2   Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University of Munich, Munich, Germany
,
Michael Spannagl
2   Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University of Munich, Munich, Germany
,
Christian Weber
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
3   DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
4   Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
,
Reinhard Lorenz
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
,
Wolfgang Siess
1   Institute for Prevention of Cardiovascular Diseases, LMU (Ludwig-Maximilians-University) Munich, Munich, Germany
3   DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
› Author Affiliations Funding The study was supported by grants from the Deutsche Forschungsgemeinschaft (SFB1123/Z01 and B08) and the August-Lenz foundation.
Further Information

Publication History

24 September 2018

09 December 2018

Publication Date:
27 January 2019 (online)

    Permissions and Reprints

Abstract

Ibrutinib and acalabrutinib are approved for B cell malignancies and novel Bruton's tyrosine kinase (Btk) inhibitors undergo clinical testing also in B cell-driven autoimmune disorders. Btk in platelets mediates platelet activation via glycoprotein (GP) VI, which is crucial for atherosclerotic plaque-induced platelet thrombus formation. This can be selectively inhibited by Btk inhibitors. Since patients on second-generation Btk inhibitors apparently show less bleeding than patients on ibrutinib, we compared the effects of ibrutinib and four novel irreversible Btk inhibitors on GPVI-dependent platelet aggregation in blood and in vitro bleeding time. Low concentrations of collagen which induced the same low degree of GPVI-mediated platelet aggregation as atherosclerotic plaque material were applied. IC50 values for collagen (0.2–0.5 µg/mL)-induced platelet aggregation after 15-minute pre-incubation were: ibrutinib 0.12 µM, BGB-3111 0.51 µM, acalabrutinib 1.21 µM, ONO/GS-4059 1.20 µM and evobrutinib 5.84 µM. Peak venous plasma concentrations of ibrutinib (0.5 µM), acalabrutinib (2 µM) and ONO/GS-4059 (2 µM) measured after anti-proliferative dosage inhibited collagen-induced platelet aggregation, but did not increase PFA-200 closure time on collagen/epinephrine. Closure times were moderately increased by 2- to 2.5-fold higher concentrations of these inhibitors, but not by BGB-3111 (1 µM) and evobrutinib (10 µM). Prolonging platelet drug exposure to 60 minutes lowered IC50 values of any Btk inhibitor for GPVI-mediated aggregation by several fold, and 5- to 10-fold below anti-proliferative therapeutic drug plasma levels. In conclusion, low blood concentrations of ibrutinib and the novel Btk inhibitors suffice for GPVI selective platelet inhibition relevant for atherothrombosis but do not impair primary haemostasis.

Keywords

Btk inhibitor - platelet aggregation - bleeding - PFA - GPVI
 

  • References

  • 1 Honigberg LA, Smith AM, Sirisawad M. , et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107 (29) 13075-13080
    CrossrefPubMedGoogle Scholar
  • 2 Byrd JC, Furman RR, Coutre SE. , et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (01) 32-42
    CrossrefPubMedGoogle Scholar
  • 3 Wang ML, Rule S, Martin P. , et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369 (06) 507-516
    CrossrefPubMedGoogle Scholar
  • 4 Byrd JC, Furman RR, Coutre SE. , et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125 (16) 2497-2506
    CrossrefPubMedGoogle Scholar
  • 5 Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8 (20) 1137-1140
    CrossrefPubMedGoogle Scholar
  • 6 Oda A, Ikeda Y, Ochs HD. , et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 2000; 95 (05) 1663-1670
    PubMedGoogle Scholar
  • 7 Penz S, Reininger AJ, Brandl R. , et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19 (08) 898-909
    CrossrefPubMedGoogle Scholar
  • 8 Schulz C, Penz S, Hoffmann C. , et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103 (04) 356-367
    CrossrefPubMedGoogle Scholar
  • 9 Reininger AJ, Bernlochner I, Penz SM. , et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55 (11) 1147-1158
    CrossrefPubMedGoogle Scholar
  • 10 Jamasbi J, Megens RT, Bianchini M. , et al. Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. J Am Coll Cardiol 2015; 65 (22) 2404-2415
    CrossrefPubMedGoogle Scholar
  • 11 Mojica Muñoz AK, Jamasbi J, Uhland K. , et al. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Thromb Haemost 2017; 117 (08) 1651-1659
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Busygina K, Jamasbi J, Seiler T. , et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood 2018; 131 (24) 2605-2616
    CrossrefPubMedGoogle Scholar
  • 13 Wang ML, Blum KA, Martin P. , et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126 (06) 739-745
    CrossrefPubMedGoogle Scholar
  • 14 Shillitoe B, Gennery A. X-Linked Agammaglobulinaemia: outcomes in the modern era. Clin Immunol 2017; 183: 54-62
    CrossrefPubMedGoogle Scholar
  • 15 Stewart DM, Lian L, Nelson DL. The clinical spectrum of Bruton's agammaglobulinemia. Curr Allergy Asthma Rep 2001; 1 (06) 558-565
    CrossrefPubMedGoogle Scholar
  • 16 Lipsky AH, Farooqui MZ, Tian X. , et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2015; 100 (12) 1571-1578
    CrossrefPubMedGoogle Scholar
  • 17 Byrd JC, Harrington B, O'Brien S. , et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374 (04) 323-332
    CrossrefPubMedGoogle Scholar
  • 18 Bye AP, Unsworth AJ, Desborough MJ. , et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv 2017; 1 (26) 2610-2623
    CrossrefPubMedGoogle Scholar
  • 19 Nicolson PLR, Hughes CE, Watson S. , et al. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI. Haematologica 2018 Doi: 10.3324/haematol.2018.193391
    PubMedGoogle Scholar
  • 20 Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood 2003; 102 (10) 3592-3599
    CrossrefPubMedGoogle Scholar
  • 21 Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins JM. Ibrutinib inhibits platelet integrin alphaiibbeta3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2326-2335
    CrossrefPubMedGoogle Scholar
  • 22 Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood 2014; 124 (13) 2013-2024
    CrossrefPubMedGoogle Scholar
  • 23 Calquence. Full prescribing information; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf . Accessed January 8, 2019
    PubMedGoogle Scholar
  • 24 Walter HS, Rule SA, Dyer MJ. , et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016; 127 (04) 411-419
    CrossrefPubMedGoogle Scholar
  • 25 Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 2016; 9 (01) 80
    CrossrefPubMedGoogle Scholar
  • 26 ClinicalTrials.gov. A study of efficacy and safety of M2951 in subjects with relapsing multiple sclerosis; 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT02975349?term=evobrutinib&rank=6 . Accessed January 8, 2019
    PubMedGoogle Scholar
  • 27 Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96 (06) 781-788
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Bampalis VG, Brantl SA, Siess W. Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry. J Thromb Haemost 2012; 10 (08) 1710-1714
    CrossrefPubMedGoogle Scholar
  • 29 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21 (Suppl. 02) 106-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 von Pape KW, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000; 98 (04) 295-299
    CrossrefPubMedGoogle Scholar
  • 31 Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6 (03) 444-450
    CrossrefPubMedGoogle Scholar
  • 32 Advani RH, Buggy JJ, Sharman JP. , et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31 (01) 88-94
    PubMedGoogle Scholar
  • 33 Barf T, Covey T, Izumi R. , et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 2017; 363 (02) 240-252
    CrossrefPubMedGoogle Scholar
  • 34 Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006; 108 (08) 2596-2603
    CrossrefPubMedGoogle Scholar
  • 35 Kazianka L, Drucker C, Skrabs C. , et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017; 31 (05) 1117-1122
    CrossrefPubMedGoogle Scholar
  • 36 Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15 (05) 835-847
    CrossrefPubMedGoogle Scholar
  • 37 Walter HS, Jayne S, Rule SA. , et al. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood 2017; 129 (20) 2808-2810
    CrossrefPubMedGoogle Scholar
  • 38 Chen J, Kinoshita T, Gururaja T. , et al. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). Eur J Haematol 2018 Doi: 10.1111/ejh.13148
    PubMedGoogle Scholar
  • 39 Lorenz RL, Boehlig B, Uedelhoven WM, Weber PC. Superior antiplatelet action of alternate day pulsed dosing versus split dose administration of aspirin. Am J Cardiol 1989; 64 (18) 1185-1188
    CrossrefPubMedGoogle Scholar
  • 40 Ungerer M, Rosport K, Bültmann A. , et al. Novel antiplatelet drug Revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123 (17) 1891-1899
    CrossrefPubMedGoogle Scholar
  • 41 ClinicalTrials.gov. Revacept in symptomatic carotid stenosis; 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT01645306 . Accessed December 5, 2016
    PubMedGoogle Scholar
  • 42 ClinicalTrials.gov. Intracoronary stenting and antithrombotic regimen: lesion platelet adhesion as selective target of endovenous Revacept (ISAR-PLASTER); 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT03312855 . Accessed December 5, 2018
    PubMedGoogle Scholar
  • 43 Alshehri OM, Hughes CE, Montague S. , et al. Fibrin activates GPVI in human and mouse platelets. Blood 2015; 126 (13) 1601-1608
    CrossrefPubMedGoogle Scholar
  • 44 Mammadova-Bach E, Ollivier V, Loyau S. , et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015; 126 (05) 683-691
    CrossrefPubMedGoogle Scholar
  • 45 Mangin PH, Onselaer MB, Receveur N. , et al. Immobilized fibrinogen activates human platelets through glycoprotein VI. Haematologica 2018; 103 (05) 898-907
    CrossrefPubMedGoogle Scholar
  • 46 Ebrahim M, Jamasbi J, Adler K. , et al. Dimeric glycoprotein VI binds to collagen but not to fibrin. Thromb Haemost 2018; 118 (02) 351-361
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Ungerer M, Li Z, Baumgartner C. , et al. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One 2013; 8 (08) e71193
    CrossrefPubMedGoogle Scholar
  • 48 Jamasbi J, Megens RT, Bianchini M. , et al. Cross-linking GPVI-Fc by anti-Fc antibodies potentiates its inhibition of atherosclerotic plaque- and collagen-induced platelet activation. JACC Basic Transl Sci 2016; 1 (03) 131-142
    CrossrefPubMedGoogle Scholar